Gore to Highlight Real-World Aortic Data at 45th Annual VEITHsymposium®

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

W. L. Gore & Associates, Inc. (Gore) will highlight data gleaned from its Global Registry for Endovascular Aortic Treatment (GREAT) Study at the 45th Annual Symposium on Vascular and Endovascular Issues, VEITHsymposium® in New York. The company is featuring the data in multiple presentations facilitated by lead investigators. GREAT is the largest industry-sponsored registry of aortic stent grafts with enrollment and follow-up data from over 100 sites across 13 countries.

“We launched this registry in 2010 to evaluate and better understand how our family of aortic devices perform in real-world applications, and as a reflection of our continued commitment to advancing patient care in the treatment of aortic disease,” said Eric Zacharias, Vascular Business Leader. “The GREAT study draws from a pool of 5,000 patients who received one or more of the GORE® EXCLUDER® AAA Endoprostheses, GORE® EXCLUDER® Iliac Branch Endoprostheses, or Conformable GORE® TAG® Thoracic Endoprostheses. We are excited to share some of the conclusions and better inform our product offerings.”

GREAT had broad inclusion criteria with minimal exclusion criteria to more accurately reflect real world clinical practice. Treatment results will be tracked for 10 years. This follow-up has and will continue to provide valuable insights into the long-term durability and behavior of Gore aortic endografts.

“Traditionally, the industry has captured and shared data on migration, endoleak rates, rupture, conversions, and a few other data points,” said Ross Milner, Professor of Surgery and Co-Director of the Center for Aortic Diseases at the University of Chicago Medical Center and National Co-Principal Investigator for GREAT in the US. In contrast, the GREAT investigators have been able to query the data to get insights into previously unanswered, rarely asked, or often unexplored areas of treatment. Our lunch symposium will explore a few of those topics.”

Panel discussions on GREAT and the resulting observations will take place in the Main Pavilion, Mercury Ballroom, starting 12 p.m. EST Friday, November 16. The discussion will include the comprehensive portfolio of aortic products.

  • Friday, Nov. 16: GREAT aortic endografting questions: What does the data reveal?

Pierre Galvagni Silveira, MD, Florianopolis, Brazil
Andrew Holden, MD, Auckland, New Zealand
Santi Trimarchi, MD, Milan, Italy

  • The GREAT update: A review of one of the largest clinical registries for abdominal and thoracic aortic devices
    Beth Tohill, PhD, Flagstaff, Arizona
  • Acute and chronic Type B aortic dissections: Exploring the nuances behind the data
    Dennis Gable, MD, Dallas, Texas
  • Noncylindrical neck morphology: Incidence, effects, and risk of reintervention
    William Shutze, MD, Dallas, Texas
  • Performance in the narrow distal aorta: Findings and implications
    Ross Milner, MD, Chicago

In addition to GREAT Registry discussions, Gore Medical will be hosting daily educational events at VEITHsymposium 2018, see full agenda here.

For more information on Gore aortic portfolio of products, visit www.goremedical.com/aortic.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles